Therapeutic Asset Ratings
8,400 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Anti-Cd19/20-Car Vector-Transduced T Cells
B Cell Lymphoma
University Hospital, Basel, Switzerland
P1/2
CCC
(53)
Anti-Gd2-Car Engineered T Cells
Neuroblastoma
Shenzhen Geno-Immune Medical Institute
P1/2
CCC
(53)
Atezolizumab
Cholangiocarcinoma
Arbele Pty Ltd
P1/2
CCC
(53)
azd5991
Acute Myeloid Leukemia
AstraZeneca
P1/2
CCC
(53)
Bms-907351
Gliosarcoma
M.D. Anderson Cancer Center
P1/2
CCC
(53)
Calcium folinate pentahydrate
Clinical Stage III Cutaneous Melanoma AJCC v8
Immuneering Corporation
P1/2
CCC
(53)
Calcium folinate pentahydrate
Head and Neck Squamous Cell Carcinoma
Neonc Technologies, Inc.
P1/2
CCC
(53)
Calcium folinate pentahydrate
KRAS Mutation-Related Tumors
Institut de Recherches Internationales Servier
P1/2
CCC
(53)
Calcium folinate pentahydrate
Small Cell Lung Carcinoma
Seagen, a wholly owned subsidiary of Pfizer
P1/2
CCC
(53)
Chimeric Antigen Receptor Modified T Cells Infusion
AML
Peking University People's Hospital
P1/2
CCC
(53)
Cyclophosphamide
Locally Advanced or Metastatic Solid Tumors
Exelixis
P1/2
CCC
(53)
Cyclophosphamide
Locally Advanced Solid Tumor
Mohammed Milhem
P1/2
CCC
(53)
Cyclophosphamide
Malignant Glioma
Beijing Biotech
P1/2
CCC
(53)
Cytosin-Arabinosid
Richter Syndrome
National Heart, Lung, and Blood Institute (NHLBI)
P1/2
CCC
(53)
DARATUMUMAB
Hodgkins Lymphoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
P1/2
CCC
(53)
Daraxonrasib
Non-Small Cell Lung Carcinoma
Revolution Medicines, Inc.
P1/2
CCC
(53)
DEXAMETHASONE
Refractory Precursor T-Lymphoblastic Lymphoma/Leukemia
Princess Maxima Center for Pediatric Oncology
P1/2
CCC
(53)
Docetaxel
Digestive System Cancer
National University Hospital, Singapore
P1/2
CCC
(53)
Durvalumab
Peritoneal Neoplasm
AstraZeneca
P1/2
CCC
(53)
Eflornithine
Carcinoma
Aminex Therapeutics, Inc.
P1/2
CCC
(53)
Eli-002 7P
KRAS G12D
Elicio Therapeutics
P1/2
CCC
(53)
Eloxatin
Cutaneous Melanoma
Immuneering Corporation
P1/2
CCC
(53)
en001
Duchenne Muscular Dystrophy
ENCell
P1/2
CCC
(53)
Enoxaparin
Morbid Obesity
Alexandria University
P1/2
CCC
(53)
Entinostat
Exocrine Pancreatic Carcinoma
National Cancer Institute (NCI)
P1/2
CCC
(53)
Showing 401 to 425 of 8,400 assets
Previous
Page 17 of 336
Next